1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Sandoz Offers Further Financials Ahead Of Spinoff

Supplement To Listing Prospectus Includes Combined And Pro-Forma First-Half Statements

 
• By Dave Wallace

With around a month to go until Sandoz is expected to become a standalone company following its spinoff from parent Novartis, the firm has published additional financial information ahead of a shareholders meeting in mid-September.

Spinoff spelled out in letters on orange cubes against yellow background
Sandoz’s spinoff from Novartis is rapidly approaching • Source: Shutterstock

As Sandoz inches closer to its expected spinoff from parent company Novartis in just under a month, the firm has supplied further financial details for the first half of 2023, along with future forecasts, as it prepares to become a standalone unit.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.